Clinical Trials
NK Cell Therapy Plus HAIC for Locally Advanced Hepatocellular Carcinoma: Phase IIa Trial
Kim et alCancer Research and Treatment

In an open-label, multicenter, phase IIa clinical trial, investigators assessed the efficacy and safety of locoregional high-dose autologous natural killer (NK) cell therapy combined with hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced hepatocellular carcinoma (HCC) refractory to standard care.
The treatment protocol required patients to initially receive two cycles of HAIC with 5-fluorouracil and cisplatin. Patients achieving stable disease or better subsequently received two additional HAIC cycles followed by hepatic arterial infusions of autologous NK cells for up to two cycles. Out of 17 enrolled patients, 16 were evaluable for therapeutic response assessed via modified RECIST for HCC.
The primary endpoint of independent review committee (IRC)-assessed objective response rate (ORR) was 68.75% (exact 95% CI, 41.34%–88.98%), comprising a complete response rate of 18.75% and a partial response rate of 50.00%. Investigator-assessed ORR was 62.50%, and both IRC and investigator reviews confirmed a disease control rate of 100%. Median duration of response was 12.65 months by IRC and 10.48 months by investigator assessment. Investigator-assessed median time to progression was 16.82 months, whereas IRC-assessed time to progression was not reached. Median overall survival reached 24.05 months across the cohort.
From a tolerability perspective, no severe NK cell-related toxicities occurred during treatment. The regimen showed promising antitumor activity and acceptable feasibility, though randomized controlled trials remain necessary to isolate the specific incremental clinical benefit attributable to NK cell therapy.
Key Takeaways
- Locoregional autologous natural killer cell therapy combined with hepatic arterial infusion chemotherapy demonstrated an independent review committee-assessed objective response rate of 68.75% (exact 95% CI, 41.34%–88.98%), including an 18.75% complete response rate, a 50.00% partial response rate, and a 100% disease control rate in evaluable patients.
- Patients achieved a median overall survival of 24.05 months and a median duration of response of 12.65 months by independent review (10.48 months by investigator assessment), with median time to progression not reached by independent review and 16.82 months by investigator evaluation.
- Locoregional administration of high-dose autologous natural killer cells demonstrated an acceptable safety profile, with no severe natural killer cell-related toxicities observed during the trial.
Read the original sourceCancer Research and Treatment
